高级检索
当前位置: 首页 > 详情页

Establishing Reliable Cu-64 Production Process: From Target Plating to Molecular Specific Tumor Micro-PET Imaging.

文献详情

资源类型:
Pubmed体系:
机构: [1]College of Chemistry, Sichuan University, Chengdu 610064, China [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China [3]Department of Biomedical Engineering, College of Engineering, Peking University, Beijing 100871, China
出处:

关键词: copper-64 solid target Rituximab positron emission tomography (PET)

摘要:
Copper-64 is a useful radioisotope for positron emission tomography (PET). Due to the wide range of applications, the demand of 64Cu with low metallic impurities is increasing. Here we report a simple method for the efficient production of high specific activity 64Cu using a cyclotron for biomedical application. We designed new equipment based on the plating of enriched 64Ni as the target, and used automated ion exchange chromatography to purify copper-64 efficiently after irradiation and dissolution of the target in good radiochemical and chemical yield and purity. The 64Cu radionuclide produced using 99.32% enriched 64Ni with a density of 61.4 ± 5.0 mg/cm², reaching a total radioactivity greater than 200 mCi, with specific activity up to 5.6 GBq/μmoL. It was further incorporated into modified monoclonal antibody DOTA-rituximab to synthesize 64Cu-DOTA-rituximab, which was used successfully for micro-PET imaging.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 化学
小类 | 3 区 有机化学
最新[2023]版:
大类 | 2 区 化学
小类 | 3 区 生化与分子生物学 3 区 化学:综合
第一作者:
第一作者机构: [1]College of Chemistry, Sichuan University, Chengdu 610064, China [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Prognostic Value of Interim and Posttherapy F-18-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas [2]Evaluation of Proton Therapy Accuracy Using a PMMA Phantom and PET Prediction Module. [3]The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis. [4]An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging [5]Micro PET imaging of F-18-Fluoromisonidazole in an MDA-MB-231 triple negative human breast cancer xenograft model [6]Significant value of F-18-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy [7]Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial [8]Invasive Field Radiotherapy Combined with Rituximab Versus Rituximab Alone for Consolidation Therapy in Stage III Follicular Lymphoma Patients Response to R-CHOP Chemotherapy: A Randomized Clinical Study [9]Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. [10]Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

资源点击量:46425 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号